Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
